UEGW 2019 - Edward Loftus om tofacitinib långtidsuppföljning 5,5 år

UEGW 2019 - Dr. Edvard Loftus berättar om sitt abstract OP213 ”Tofacitinib, an oral janus kinase inhibitor, in the treatment of Ulcerative Colitis: an interim analysis of an open-label, long-term extension study with up to 5,5 years of treatment”.